Given that anti‐CXCL8[54] and anti‐NET therapies[55] are currently being evaluated in clinical trials for the treatment of solid tumors, our study also proposes SKAP1 as a novel biomarker to identify patients with colon cancer who may benefit from these therapies. Here, CXCL8 is linked to colonic neoplasm.